Citigroup Upgrades Sabra Health Care REIT to Buy, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Nicholas Joseph has upgraded Sabra Health Care REIT from Neutral to Buy, raising the price target from $17 to $20.
September 13, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has upgraded Sabra Health Care REIT to Buy, with a new price target of $20, indicating a positive outlook for the stock.
The upgrade from Neutral to Buy by Citigroup, along with an increased price target, suggests a positive sentiment and potential for stock price appreciation. This is likely to attract investor interest and could lead to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100